Product logins

Find logins to all Clarivate products below.


Global Consequences of Smoking Cessation: NSCLC Incidence over the Next Two Decades

The strongest risk factor that drives change in the incidence of non-small-cell lung cancer (NSCLC) is the historical prevalence of smoking. The long lag between the initiation of tobacco use and the development of lung cancer is an indicator that we have only seen the tip of the iceberg regarding long-term effects of the smoking epidemic. This finding is compounded by the effect of population aging and growth. Owing to the shift in disease risk, we do not use historical NSCLC incidence to predict future incidence of NSCLC. Changing patterns in risk, based on evolving smoking patterns, following increased awareness and investment in tobacco control strategies need to be incorporated in forecasting NSCLC incidence.

Related Market Assessment Reports

Report
Non-Small-Cell Lung Cancer | Disease Landscape & Forecast | G7 | 2024
The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.), which…
Report
Small-Cell Lung Cancer | Disease Landscape & Forecast | G7 | 2024
The small-cell lung cancer (SCLC) treatment landscape is dominated by chemotherapy and chemoradiotherapy. In the last 30 years, only two immunotherapies have been approved in this indication:…
Report
Non-Small-Cell Lung Cancer | Treatment Sequencing | US | 2024
Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…
Report
Non-Small-Cell Lung Cancer | Current Treatment: Physician Insights | US | May 2024
Immune checkpoint inhibitors continue to dominate the treatment of non-small-cell lung cancer (NSCLC), while biomarker-based approaches are driving increasing patient segmentation. 2023 saw the…
Report
Non-Small-Cell Lung Cancer | Disease Landscape & Forecast | G7 | 2023
The multi-billion-dollar non-small-cell lung cancer (NSCLC) market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as…